Alzheimer's Disease - Pipeline Review, H1 2018

Publisher Name :
Date: 20-Feb-2018
No. of pages: 1203
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease - Pipeline Review, H1 2018, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 23, 50, 56, 1, 253, 99 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 104 and 43 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).

  • The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Alzheimer's Disease - Pipeline Review, H1 2018

Table of Contents

Table of Contents 2
Introduction 10
Alzheimer's Disease - Overview 11
Alzheimer's Disease - Therapeutics Development 12
Alzheimer's Disease - Therapeutics Assessment 72
Alzheimer's Disease - Companies Involved in Therapeutics Development 98
Alzheimer's Disease - Drug Profiles 188
Alzheimer's Disease - Dormant Projects 1092
Alzheimer's Disease - Discontinued Products 1123
Alzheimer's Disease - Product Development Milestones 1130
Appendix 1142

List of Tables

Number of Products under Development for Alzheimer's Disease, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Alzheimer's Disease - Pipeline by AB Science SA, H1 2018
Alzheimer's Disease - Pipeline by AbbVie Inc, H1 2018
Alzheimer's Disease - Pipeline by AC Immune SA, H1 2018
Alzheimer's Disease - Pipeline by Acadia Pharmaceuticals Inc, H1 2018
Alzheimer's Disease - Pipeline by Accera Inc, H1 2018
Alzheimer's Disease - Pipeline by Actinogen Medical Ltd, H1 2018
Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals Inc, H1 2018
Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, H1 2018
Alzheimer's Disease - Pipeline by Aequus Pharmaceuticals Inc, H1 2018
Alzheimer's Disease - Pipeline by AFFiRiS AG, H1 2018
Alzheimer's Disease - Pipeline by Alector LLC, H1 2018
Alzheimer's Disease - Pipeline by Allergan Plc, H1 2018
Alzheimer's Disease - Pipeline by Allgenesis Biotherapeutics Inc, H1 2018
Alzheimer's Disease - Pipeline by Allinky Biopharma, H1 2018
Alzheimer's Disease - Pipeline by ALSP Inc, H1 2018
Alzheimer's Disease - Pipeline by Alzhyme Pty Ltd, H1 2018
Alzheimer's Disease - Pipeline by Alzinova AB, H1 2018
Alzheimer's Disease - Pipeline by AlzProtect SAS, H1 2018
Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H1 2018
Alzheimer's Disease - Pipeline by Amgen Inc, H1 2018
Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp, H1 2018
Alzheimer's Disease - Pipeline by Annexon Inc, H1 2018
Alzheimer's Disease - Pipeline by Aphios Corp, H1 2018
Alzheimer's Disease - Pipeline by Apodemus AB, H1 2018
Alzheimer's Disease - Pipeline by Applied Research using OMIC Sciences SL, H1 2018
Alzheimer's Disease - Pipeline by Aptevo Therapeutics Inc, H1 2018
Alzheimer's Disease - Pipeline by Araclon Biotech SL, H1 2018
Alzheimer's Disease - Pipeline by Archer Pharmaceuticals Inc, H1 2018
Alzheimer's Disease - Pipeline by ArmaGen Inc, H1 2018
Alzheimer's Disease - Pipeline by Asceneuron SA, H1 2018
Alzheimer's Disease - Pipeline by Astellas Pharma Inc, H1 2018
Alzheimer's Disease - Pipeline by AstraZeneca Plc, H1 2018
Alzheimer's Disease - Pipeline by Aucta Pharmaceuticals LLC, H1 2018
Alzheimer's Disease - Pipeline by Avineuro Pharmaceuticals Inc, H1 2018
Alzheimer's Disease - Pipeline by Axon Neuroscience SE, H1 2018
Alzheimer's Disease - Pipeline by Axovant Sciences Ltd, H1 2018
Alzheimer's Disease - Pipeline by Axsome Therapeutics Inc, H1 2018
Alzheimer's Disease - Pipeline by Axxam SpA, H1 2018
Alzheimer's Disease - Pipeline by AZTherapies Inc, H1 2018
Alzheimer's Disease - Pipeline by Beactica AB, H1 2018
Alzheimer's Disease - Pipeline by Berg LLC, H1 2018
Alzheimer's Disease - Pipeline by BioArctic AB, H1 2018
Alzheimer's Disease - Pipeline by Biogen Inc, H1 2018
Alzheimer's Disease - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018
Alzheimer's Disease - Pipeline by BioHealthonomics Inc, H1 2018
Alzheimer's Disease - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2018
Alzheimer's Disease - Pipeline by Bristol-Myers Squibb Co, H1 2018
Alzheimer's Disease - Pipeline by Bsim2, H1 2018
Alzheimer's Disease - Pipeline by Cantabio Pharmaceuticals Inc, H1 2018
Alzheimer's Disease - Pipeline by Cardax Inc, H1 2018
Alzheimer's Disease - Pipeline by Carna Biosciences Inc, H1 2018
Alzheimer's Disease - Pipeline by Celon Pharma SA, H1 2018
Alzheimer's Disease - Pipeline by CHA Bio & Diostech Co Ltd, H1 2018
Alzheimer's Disease - Pipeline by Clera Inc, H1 2018
Alzheimer's Disease - Pipeline by Cognition Therapeutics Inc, H1 2018
Alzheimer's Disease - Pipeline by Cognosci Inc, H1 2018
Alzheimer's Disease - Pipeline by CohBar Inc, H1 2018
Alzheimer's Disease - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2018
Alzheimer's Disease - Pipeline by ConSynance Therapeutics Inc, H1 2018
Alzheimer's Disease - Pipeline by Corium International Inc, H1 2018
Alzheimer's Disease - Pipeline by Coronis NeuroSciences Ltd, H1 2018
Alzheimer's Disease - Pipeline by Cortice Biosciences Inc, H1 2018
Alzheimer's Disease - Pipeline by Cotinga Pharmaceuticals Inc, H1 2018
Alzheimer's Disease - Pipeline by Crossbeta Biosciences BV, H1 2018
Alzheimer's Disease - Pipeline by Cypralis Ltd, H1 2018

List of Figures

Number of Products under Development for Alzheimer's Disease, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
  • Global Alzheimer's Disease Drug Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93
    According to our LPI (LP Information) latest study, the global Alzheimer's Disease Drug market size was valued at US$ 3539.3 million in 2023. With growing demand in downstream market, the Alzheimer's Disease Drug is forecast to a readjusted size of US$ 3943.3 million by 2030 with a CAGR of 1.6% during review period. The research report highlights the growth potential of the global Alzheimer's Disease Drug market. Alzheimer's Disease Drug are expected to show stable growth in the future m......
  • Alzheimer's Drugs - Global Market Insights and Sales Trends 2024
    Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 97
    The global Alzheimer's Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Alzheimer's Drugs in various end use industries. The expanding demands from the Under 65 Years Old and 65 and Above 65 Years Old, are propelling Alzheimer's Drugs market. Acetylcholinesterase (AChE) Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by t......
  • Alzheimer Disease Drugs Industry Forecasts - China Focus
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 111
    This study focuses on China's Alzheimer Disease Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and servi......
  • Alzheimer Disease Drugs Companies in China
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 74
    This study focuses on China's Alzheimer Disease Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumpt......
  • Alzheimer Disease Drugs Markets in China
    Published: 27-Nov-2023        Price: US 4000 Onwards        Pages: 239
    China's demand for Alzheimer Disease Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacit......
  • Global Alzheimer's Disease Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 12-Sep-2023        Price: US 3380 Onwards        Pages: 117
    Market Overview of Global Alzheimer's Disease Drug market: According to our latest research, the global Alzheimer's Disease Drug market looks promising in the next 5 years. As of 2022, the global Alzheimer's Disease Drug market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Alzheimer's disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills and,......
  • Global Dementia and Movement Disorder Treatment Market Insights, Forecast to 2029
    Published: 11-Aug-2023        Price: US 4900 Onwards        Pages: 110
    Dementia is a collective term for disorders characterized by progressive degeneration of the brain. It impairs memory and affects behavioral, emotional, and cognitive abilities. The neuronal death or neuronal malfunction associated with the disorder manifests as shifts in mood and personality changes, difficulty in performing activities, loss of memory, and aphasia. Market Analysis and Insights: Global Dementia and Movement Disorder Treatment Market The global Dementia and Movement......
  • Global Nicergoline Market Insights, Forecast to 2029
    Published: 04-Jul-2023        Price: US 4900 Onwards        Pages: 112
    The global Nicergoline market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period. The US & Canada market for Nicergoline is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029. The China market for Nicergoline is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR......
  • Global Oxiracetam Market Research Report 2023
    Published: 21-Apr-2023        Price: US 2900 Onwards        Pages: 69
    Highlights The global Oxiracetam market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes. North American market for Oxiracetam is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029. Asia-Pacific ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs